Erythromycin Stearate Tablets

Erythromycin stearate belongs to the macrolide antibiotics, and has antibacterial activity against Staphylococcus, various groups of Streptococcus and Gram-positive bacilli. Neisseria, Haemophilus influenzae, Bordetella pertussis, etc. are also sensitive to this product. This product also has antibacterial activity against various anaerobic bacteria except Bacteroides fragilis and Fusobacterium; it also has inhibitory effects on Legionella, Campylobacter fetus, some spirochetes, Mycoplasma pneumoniae, Rickettsia and Chlamydia. This product is an antibacterial agent, but it also has a bactericidal effect on some bacteria at high concentrations. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor site (P site), blocking the transfer RNA (t-RNA) binding to the P site, and also blocking the displacement of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis. Erythromycin stearate is only effective against bacteria that actively divide.

Erythromycin stearate

1. This product is used as an alternative to penicillin-allergic patients to treat the following infections: acute tonsillitis, acute pharyngitis, sinusitis caused by hemolytic streptococci, pneumococci, etc.; scarlet fever and cellulitis caused by hemolytic streptococci; diphtheria and diphtheria carriers; gas gangrene, anthrax, tetanus; actinomycosis; syphilis; listeriosis, etc. 2. Legionnaires' disease. 3. Mycoplasma pneumonia. 4. Chlamydia pneumoniae pneumonia. 5. Urinary and reproductive system infections caused by other chlamydia and mycoplasma. 6. Chlamydia trachomatis conjunctivitis. 7. Gonorrhea infection. 8. Oral infection caused by anaerobic bacteria. 9. Campylobacter jejuni enteritis. 10. Whooping cough. 11. Preventive medication for recurrent rheumatic fever, infective endocarditis (after rheumatic heart disease, congenital heart disease, heart valve replacement surgery), oral and upper respiratory tract medical operations (alternative to penicillin).

Oral administration: 0.75-2g per day for adults, divided into 3-4 times; 20-40mg/kg per day for children, divided into 3-4 times. For the treatment of Legionnaires' disease, 0.5-1.0g per time, 4 times a day for adults. When used as a preventive medication for recurrent rheumatic fever, 0.25g per time, 2 times a day. When used as a preventive medication for infective endocarditis, 1g is taken orally 1 hour before surgery, and 0.5g is taken 6 hours after surgery.

1. Gastrointestinal reactions are common, including diarrhea, nausea, vomiting, upper and middle abdominal pain, pain in the mouth and tongue, decreased appetite, etc., and the incidence is related to the dose. 2. Hepatotoxicity is rare, and patients may experience fatigue, nausea, vomiting, abdominal pain, fever, abnormal liver function, and occasionally jaundice. 3. When used in large doses (ge; 4g/day), especially in patients with liver and kidney diseases or elderly patients, hearing loss may occur, which is mainly related to excessive blood drug concentration (; 12mg/L), and most of them can be recovered after drug withdrawal. 4. Allergic reactions are manifested as drug fever, rash, eosinophilia, etc., with an incidence of about 0.5% to 1%. 5. Others: Occasionally there are arrhythmias, oral or vaginal candidiasis.

It is contraindicated for patients who are allergic to erythromycin.

1. This product can inhibit the metabolism of antiepileptic drugs such as carbamazepine and valproic acid, resulting in increased blood concentrations of the latter and toxic reactions. This product can inhibit the metabolism of the latter and prolong its duration of action when used in combination with alfentanil. This product can increase cardiac toxicity when used in combination with antihistamines such as astemizole or terfenadine, and can increase the blood concentration of the latter and produce nephrotoxicity when used in combination with cyclosporine. 2. It has an antagonistic effect with chloramphenicol and lincosamides, and it is not recommended to use them together. 3. This product is an antibacterial agent that can interfere with the bactericidal efficacy of penicillin. Therefore, when rapid bactericidal effects are required, such as the treatment of meningitis, the two should not be used together. 4. Patients who take warfarin for a long time can prolong the prothrombin time when using this product, thereby increasing the risk of bleeding. Elderly patients should pay special attention. When the two must be used together, the dose of warfarin should be appropriately adjusted and the prothrombin time should be closely observed. 5Except for dihydroxypropylphylline, the combination of this product with xanthines can reduce the hepatic clearance of aminophylline, leading to increased serum aminophylline concentrations and (or) increased toxic reactions. This phenomenon is more likely to occur after 6 days of combined use, and the reduction in aminophylline clearance is proportional to the erythromycin serum peak. Therefore, the dose of xanthines should be adjusted during and after the combined treatment of the two. 6Combination with other hepatotoxic drugs may enhance hepatotoxicity. 7The combination of high-dose erythromycin and ototoxic drugs, especially in patients with renal impairment, may increase ototoxicity. 8When used in combination with lovastatin, its metabolism can be inhibited and blood concentrations can be increased, which may cause rhabdomyolysis. When used in combination with midazolam or triazolam, the clearance of both can be reduced and their effects can be enhanced.

Keep away from light, tightly closed and in a dry place.

0.25g (250,000 units) based on C37H67NO13

Sichuan Pharmaceutical, Inc.

• Founded in:

  2005-07-14

• Address:

  No. 18, Baiye Road, High-tech West District, Chengdu

• Tax NO.:

  91510100777457202W

• Registered Funds:

  80 million yuan

• Website:

  Log in to view

• Email:

  Log in to view